SCHEDULE: Paradigm BioCapital Discloses Stake in Assembly Biosciences

Paradigm BioCapital entities and Senai Asefaw, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Assembly Biosciences, Inc. common stock as of May 4, 2026.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. have collectively filed a Schedule 13G, indicating their beneficial ownership of Assembly Biosciences, Inc. common stock.
• As of May 4, 2026, the total beneficial ownership reported is 865,251 shares, representing 5.4% of the company's outstanding common stock.
• Paradigm BioCapital International Fund Ltd. directly holds 758,963 shares, accounting for 4.8% of the outstanding shares.
• The filing specifies that Paradigm BioCapital Advisors LP acts as the investment manager for the Fund and separately managed accounts, while Paradigm BioCapital Advisors GP LLC is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP.
• Each reporting person disclaims beneficial ownership of shares not directly owned by them.
• The percentages are based on 15,892,608 shares of Common Stock outstanding as of April 10, 2026, as reported by Assembly Biosciences in a prior filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company.

Positives

• Significant institutional ownership reported by Paradigm BioCapital entities, potentially indicating confidence in Assembly Biosciences' future prospects.
• Clear disclosure of beneficial ownership and reporting structure, adhering to regulatory requirements.

Negatives

• The filing does not contain any negative financial or operational information, as it is a disclosure of beneficial ownership.
• No specific details are provided regarding the investment strategy or rationale behind acquiring the stake.

Risks

• The filing does not explicitly mention any risks. However, as with any investment, the value of Assembly Biosciences' common stock is subject to market fluctuations and company-specific performance risks.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Assembly Biosciences' future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates Paradigm BioCapital's increased interest in Assembly Biosciences, a biotechnology company, aligning with broader trends of institutional investment in the life sciences sector.

Stakeholder Impact

• Shareholders: The increased institutional ownership may be viewed positively, potentially leading to greater market liquidity and signaling investor confidence. However, it also means a larger portion of the company is held by a single entity, which could influence future corporate actions.
• Management: The filing serves as a notification to the company's management and board of directors regarding significant ownership by Paradigm BioCapital.
• Potential Investors: This filing provides transparency to other investors about the ownership structure and the presence of a significant institutional holder.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership in Assembly Biosciences, Inc. and may file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Assembly Biosciences, Schedule 13G, Paradigm BioCapital, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Institutional Investor